Abstract
Anxiety is perceived as a pervasive feeling of apprehension about some unspecified future threat to self-esteem. The somatic manifestations of anxiety are many, affecting virtually all organ systems. However, anxiety must be distinguished from other organic illnesses whose symptoms may resemble those of anxiety. A complex interaction may occur in which anxiety and organic disease may have mutually aggravating effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Redmond DE Jr, Huang YH: Current concepts. II. New evidence for a locus ceruleus-norepinephrine connection with anxiety. Life Sci 25: 2149–2162, 1979.
Paul SM, Skolnick P: Benzodiazepine receptors and psychopathological states: towards a neurobiology of anxiety. In Klein DF, Rabkin J (eds): Anxiety: new research and changing concepts. Raven Press, New York, pp 215–230, 1981.
Lader M, Petursson H: Rational use of anxiolytic/ sedative drugs. Drugs 25: 514–528, 1983.
Sheehan DV, Coleman JH, Greenblatt DJ, Jones KJ, Levine PH, Orsulak PJ, Peterson M, Schildkraut J J, Uzogara E, Watkins D: Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharm 4: 66–75, 1984.
Stroebel CF, Szarek BL, Glueck BC: Use of clomipramine in treatment of obsessive-compulsive symptomatology. J Clin Psychopharm 4: 98–100, 1984.
Brantigan CO, Brantigan TA, Joseph N: Effect of beta blockade and beta stimulation on stage fright. 72: 88–94, 1982.
Hollister LE: Clinical pharmacology of psychotherapeutic drugs, 2nd ed. Churchill-Livingstone, New York, pp 53–59, 1983.
Costa E, Guidotti A: Molecular mechanisms in the receptor action of benzodiazepines. Ann Rev Pharmacol Toxicol 19: 531–545, 1979.
Greenblatt DJ, Shader RI, Divoll M, Harmatz JS: Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol 11: 11S–16S, 1981.
Kotin J, Post RM, Goodwin FK: Drug treatment of depressed patients referred for hospitalization. Am J Psychiat 130: 1139–1141, 1973.
Vettulani J, Sulser F: Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature 257: 495–496, 1975.
Asberg M: Individualization of treatment with tricyclic compounds. Med Clin North 58: 1083–1091, 1974.
Hollister LE: Monitoring tricyclic antidepressant plasma concentrations. JAMA 241: 2530–2533, 1979.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Hollister, L.E. (1986). Drugs for Treating Anxiety and Depression. In: Maronde, R.F. (eds) Topics in Clinical Pharmacology and Therapeutics. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-4864-4_19
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4864-4_19
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-9336-1
Online ISBN: 978-1-4612-4864-4
eBook Packages: Springer Book Archive